Sarcoglycan, the heart, and skeletal muscles: new treatment, old drug?
Towbin
J A
JA
Department of Pediatrics (Cardiology, Baylor College of Medicine, One Baylor Plaza, Room 333E, Houston, Texas 77030, USA. jtowbin@bcm.umc.edu
Bowles
N E
NE
D000818:Animals; D009202:Cardiomyopathies / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D003598:Cytoskeletal Proteins / Q000172:deficiency / Q000235:genetics; D004195:Disease Models, Animal; D049030:Dystroglycans; D016189:Dystrophin / Q000172:deficiency / Q000235:genetics; D006801:Humans; D008562:Membrane Glycoproteins / Q000172:deficiency / Q000235:genetics; D051379:Mice; D009154:Mutation; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D049031:Sarcoglycans; D015398:Signal Transduction; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014700:Verapamil / Q000627:therapeutic use*
D003598:Cytoskeletal Proteins; C483081:DAG1 protein, human; D016189:Dystrophin; D008562:Membrane Glycoproteins; D049031:Sarcoglycans; D014665:Vasodilator Agents; D049030:Dystroglycans; D014700:Verapamil